Table 1 Overall and group demographic and clinical data at study entry

Age, years *

60 ± 14

53 ± 14

57 ± 14

60 ± 15

64 ±12

69 ± 11

Females, n (%)

109 (36.1)

6 (17.1)

16 (33.3)

61 (38.1)

17 (41.5)

9 (50)

Diabetes, n (%)

56 (18.5)

7 (20.0)

15 (31.0)

23 (14.3)

8 (16.3)

3 (16.7)

CAD, n (%)

108 (35.8)

9 (25.7)

17 (35.4)

56 (35)

18 (43.9)

8 (44.4)

HT, n (%) *

267 (88.4)

26 (74.3)

44 (91.7)

146 (91.3)

34 (82.9)

17 (94.4)

PVD, n (%)

70 (23.3)

4 (11.4)

16 (33.3)

33 (20.6)

11 (26.8)

6 (33.3)

CVA, n (%) *

38 (12.7)

2 (5.7)

6 (12.5)

17 (10.6)

12 (29.3)

1 (5.6)

COPD, n (%)

29 (9.6)

4 (11.4)

3 (6.3)

13 (8.1)

7 (17.1)

2 (11.1)

Dyslipidemia, n (%)

118 (39.1)

8 (22.9)

24 (50)

60 (37.5)

17 (41.5)

9 (50)

BMI kg/m ² *

25.9 ± 5.6

27.1 ± 7.7

27.5 ± 5.9

25.1 ± 4.7

24.6 ± 4.4

28.9 ± 6.9

Obesity, n (%) *

18 (6)

3 (8.6)

6 (12.5)

6 (3.8)

0

3 (16.7)

Previous transplant, n (%)*

10 (28.6)

4 (8.3)

19 (11.9)

5 (12.2)

1 (5.6)

39 (12.9)

HD, n (%) *

244 (80.8)

24 (68.6)

30 (62.5)

135 (84.4)

38 (92.7)

17 (94.4)

Duration of ESKD (months)

34 (18–60)

49 (28–111)

26 (15–56)

34 (17–60)

31 (19–54)

31 (23–58)

Time on dialysis (months)

33 (18–58)

41 (27–88)

36 (18–66)

37 (22–59)

31 (23–58)

35 (18–61)